{Reference Type}: Journal Article
{Title}: [New targets for the prevention and treatment of cirrhotic portal vein thrombosis].
{Author}: Wang YW;Ding HG;
{Journal}: Zhonghua Gan Zang Bing Za Zhi
{Volume}: 32
{Issue}: 6
{Year}: 2024 Jun 20
暂无{DOI}: 10.3760/cma.j.cn501113-20240229-00100
{Abstract}: Portal vein thrombosis (PVT) is divided into cirrhotic and non-cirrhotic PVTs. The incidence rate of PVT varies greatly among different clinical stages of cirrhosis, with an overall incidence rate of about 13.92%, and the prevalence of cirrhotic PVT following splenectomy is as high as 60%. The pathogenesis of cirrhotic PVT is still unclear. However, the activation of Janus kinase/signal transduction and activator transcription signaling pathways, the rise in the expression of von Willebrand factor, and the gut microbiota along with its metabolite trimethylamine-N-oxide play an important role in the injury of vascular endothelial cells and the formation of PVT in cirrhosis. Therefore, these could be a new target for cirrhotic PVT prevention and treatment.<BR>门静脉血栓（PVT）分为肝硬化性PVT和非肝硬化性PVT。PVT发病率在肝硬化不同临床阶段差别较大，总体发病率约为13.92%，而肝硬化脾切除术后PVT患病率高达60%。肝硬化性PVT的发病机制尚不明确，但Janus激酶/信号转导与转录激活子信号通路活化、血管性血友病因子表达增加、肠道菌群及其代谢产物三甲胺-N-氧化物在肝硬化血管内皮细胞损伤、PVT形成中具有重要作用，可能是肝硬化性PVT防治的新靶点。.